###BASE_URL###

GENET-news articles on GE rabbits

go to page: 1 2

2013-08-16 |

Neon rabbits, pigs and sheep fetuses spark ethics debate

Even as he works toward very important medical goals, Stefan Moisyadi seems to add color to everything he touches. As a lead scientist at the University of Hawaii’s Institute for Biogenesis Research, he and a team of collaborators in Turkey used DNA from jellyfish to produce living glow-in-the-dark bunnies last week.

2013-08-14 |

Rabbits genetically altered to glow in the dark

Rabbits cloned by scientists, glow in the dark. This is an attempt to improve research into treatments for life-threatening illnesses. A litter of eight rabbits was produced by researchers from Hawaii and Turkey, out of which only two glow green in the dark.

2011-06-16 |

Kenyans women farmers now go organic farming

Women are at the frontlines spearheading organic farming in Lari and their strategic role in society has only entrenched the practice to boost food security for their families and the entire community. Njeri engages in intensive cultivation of indigenous crop varieties that include cassava, yams, arrowroots, sweet potatoes, traditional maize and Norway beans in her two acre piece of land. She also rears indigenous goats, chicken and rabbits whose products are a prized treasure among local communities and external markets.

2011-03-22 |

Santarus fails to get U.S. approval for Rhucin produced by GE rabbits

Santarus Inc. said Monday the U.S. Food and Drug Administration declined to give marketing approval for its drug Rhucin. [...] Shares of Santarus fell 6 cents Monday to close at $3.19 each. The company has licensed Rhucin from the Dutch biotech company Pharming Group NV for sale in North America.

2010-10-20 |

Pharming (Netherlands) to sell drug from GE rabbits

Pharming, based in the Netherlands, is set to be the world’s first pharmaceutical group to derive a medicine from transgenic rabbits, using the milk they produce as the basis for its drug to treat a rare genetic disease. It will be only the second medicine cleared by regulators from a transgenic animal, after GTC Biotherapeutics of the US received authorisation to produce its ATryn drug, to prevent blood clots, from the milk of genetically modified goats.

2010-07-16 |

Cash key for Pharming as it seeks to milk key drug from GE rabbits

Dutch biotech Pharming needs to tell investors quickly how it is going to fund the roll-out of its lead drug as its stock takes a battering despite a regulatory boost. Pharming’s risk profile improved sharply last week when its drug Ruconest, an angioedema drug derived from rabbit milk, was recommended for approval by the European Medicines Agency (EMA) and shares jumped. But the stock has since fallen about 35 percent on worries about a possible share issue and convertible debt of 10.9 million euros which carries an early redemption option on Oct. 31.

2010-05-03 |

New Zealand’s GE authority advises against GE animal application

State science company AgResearch [...] wanted to experiment on human and monkey cell lines and smaller species of GE laboratory animals, such as cats, dogs, pigs, guinea pigs, mice, rats, rabbits, and chickens, to develop GE cows, buffalo, sheep, pigs, goats, llamas, alpacas, deer and horses. But today’s Erma staff evaluation and review report - for a hearing to be held by Erma in June - recommended those applications be declined.

2010-04-15 |

Pharming strikes Rhucin EU distribution deal

Dutch biotech firm Pharming clinched on Thursday a European distribution deal and an upfront payment for its drug Rhucin with Sweden’s Orphan Biovitrum as it prepares for its first product launch. Pharming is waiting for the European Medicines Agency (EMA) to approve the marketing of its lead product Rhucin after previous attempts were turned down. It expects EMA to issue its final opinion in the third quarter of this year.

2010-02-19 |

Pharming confident of Rhucin Europe approval in 2010 despite EUR 32.1 mill loss in 2009

Dutch biotechnology firm Pharming said it was on track to secure European approval for its key drug product Rhucin, even as it continued to operate at a loss for 2009. Pharming, which produces therapeutic proteins in the milk of genetically modified animals, reported on Thursday a net loss of 32.1 million euros ($44.07 million) in 2009 compared with a loss of 26.2 million in 2008, partly due to lower interest income.

2010-01-25 |

GE rabbits milked for human protein; drug soon for sale?

Dutch farmers are ready to start commercially milking rabbits, pending authorization from European authorities. But that doesn’t mean bunny cheese will soon be on store shelves—the genetically engineered rabbits would be milked to churn out a potentially lifesaving drug. Developed by Netherlands-based biotech firm Pharming, the rabbits have been outfitted with a human gene that produces a protein called C1 inhibitor.

go to page: 1 2

Home: GENET